Results 221 to 230 of about 253,192 (255)
Some of the next articles are maybe not open access.
Population Pharmacokinetic/ Pharmacodynamics of Interleukin-6 Receptor Inhibitor
Objective: Recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody is an innovative drug developed by China. In the clinical trial of healthy people, the innovative drug showed fairly good safety and tolerance. Model-informed drug development (MIDD) is widely used in innovative drug development.Binyi Hu +11 more
openaire +1 more source
Tocilizumab: An lnterleukin-6 Receptor Inhibitor for the Treatment of Rheumatoid Arthritis
Annals of Pharmacotherapy, 2008Objective: To review the pharmacology, pharmacokinetics, clinical trial data, and safety profile of tocilizumab, a new biologic agent targeting the lnterleukin-6 cytokine receptor. Data Sources: A systematic search of MEDLINE (1998 ...
openaire +2 more sources
Modern Rheumatology, 2013
To examine the effectiveness of tocilizumab (TCZ) in preventing joint destruction in patients with inadequate response to tumor necrosis factor inhibitors (TNF-IR) by assessing X-rays.RA patients were extracted from the Retrospective actemra investigation for optimal needs of RA patients (REACTION) study.
Yoshiya, Tanaka +13 more
openaire +2 more sources
To examine the effectiveness of tocilizumab (TCZ) in preventing joint destruction in patients with inadequate response to tumor necrosis factor inhibitors (TNF-IR) by assessing X-rays.RA patients were extracted from the Retrospective actemra investigation for optimal needs of RA patients (REACTION) study.
Yoshiya, Tanaka +13 more
openaire +2 more sources
Die Pharmazie, 2016
Objective: Sepsis is a life-threatening condition, usually accompanied by excessive inflammation. Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin (IL) 6 receptor and has been studied in various inflammatory diseases, but little is known about its effects in sepsis.
Fen Sheng, Fen Sheng +3 more
openaire +2 more sources
Objective: Sepsis is a life-threatening condition, usually accompanied by excessive inflammation. Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin (IL) 6 receptor and has been studied in various inflammatory diseases, but little is known about its effects in sepsis.
Fen Sheng, Fen Sheng +3 more
openaire +2 more sources
Cancer Research, 2007
Abstract Interleukin-6 (IL-6) is a key molecule involved in the pathogenesis of several inflammatory diseases and malignancies. Treatments that inhibit IL-6 mitigate the clinical conditions of such diseases. Here, we report on the development of a new receptor inhibitor of IL-6 (NRI) by genetically engineering tocilizumab, a humanized ...
Naoko, Yoshio-Hoshino +5 more
openaire +2 more sources
Abstract Interleukin-6 (IL-6) is a key molecule involved in the pathogenesis of several inflammatory diseases and malignancies. Treatments that inhibit IL-6 mitigate the clinical conditions of such diseases. Here, we report on the development of a new receptor inhibitor of IL-6 (NRI) by genetically engineering tocilizumab, a humanized ...
Naoko, Yoshio-Hoshino +5 more
openaire +2 more sources